https://www.prnewswire.com/news-releases/lonzas-synaffix-and-sidewinder-therapeutics-announce-multi-target-license-agreement-to-advance-development-of-nextgeneration-bispecific-adcs-302654334.html?utm_source=tldrbio.tech&utm_medium=referral&utm_campaign=biotech-pharma-updates-january-6-7-2026
/PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development...
lonzasynaffixsidewindertherapeuticsannounce
https://www.biospace.com/innovent-announces-license-agreement-with-synaffix-in-an-adc-technology-deal
Innovent Biologics, Inc. announced the signing of a non-exclusive, target-specific license agreement with Synaffix B.V., a biotechnology company focused on...
license agreementin anannouncessynaffixadc